GLP-1 RA antiobesity medications: an introduction

Author(s):

Richard Payerchin

Key Takeaways

GLP-1 receptor agonists are proving effective in reducing body mass index and enhancing patient health outcomes.
Patients are increasingly interested in understanding the benefits and mechanisms of these antiobesity medications.
Dr. Robert Kushner has significantly contributed to obesity research and treatment, focusing on nutrition and lifestyle medicine.
Northwestern University’s Feinberg School of Medicine and the Center for Lifestyle Medicine are key institutions in advancing obesity treatment.

A physician researcher and author discusses the latest information on GLP-1 RA antiobesity medications.

The new GLP-1 RA antiobesity medications are showing excellent benefits for patient body mass index and health. Patients want to know more. Here’s an introduction with Robert Kushner, MD, has made a career as a researcher and author about overweight, obesity and nutrition. He’s also a doctor who has treated patients for years through Northwestern University’s Feinberg School of Medicine and Northwestern Medicine’s Center for Lifestyle Medicine.

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!